Danaher (NYSE:DHR) Price Target Lowered to $277.00 at Robert W. Baird

Danaher (NYSE:DHR) had its target price dropped by Robert W. Baird from $278.00 to $277.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s target price would suggest a potential upside of 6.02% from the stock’s current price.

DHR has been the topic of several other reports. Stifel Nicolaus lifted their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $282.06.

Danaher Stock Down 4.0 %

Shares of DHR stock opened at $261.28 on Wednesday. The stock’s 50 day simple moving average is $270.67 and its 200 day simple moving average is $260.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market capitalization of $193.53 billion, a price-to-earnings ratio of 44.28, a PEG ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 EPS. As a group, research analysts predict that Danaher will post 7.59 EPS for the current year.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last 90 days. 11.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Danaher

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. AdvisorNet Financial Inc increased its holdings in Danaher by 11.3% in the first quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate’s stock valued at $189,000 after purchasing an additional 77 shares during the last quarter. Dynamic Advisor Solutions LLC increased its holdings in Danaher by 8.3% in the first quarter. Dynamic Advisor Solutions LLC now owns 7,744 shares of the conglomerate’s stock valued at $1,934,000 after purchasing an additional 591 shares during the last quarter. Procyon Advisors LLC increased its holdings in Danaher by 14.0% in the first quarter. Procyon Advisors LLC now owns 8,789 shares of the conglomerate’s stock valued at $2,195,000 after purchasing an additional 1,082 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Danaher by 3.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 194,515 shares of the conglomerate’s stock valued at $48,574,000 after purchasing an additional 7,076 shares during the last quarter. Finally, Thrive Wealth Management LLC grew its stake in Danaher by 4.9% in the first quarter. Thrive Wealth Management LLC now owns 6,070 shares of the conglomerate’s stock valued at $1,516,000 after acquiring an additional 283 shares during the period. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.